Tumour antigenicity in ovarian cancer.
The blastogenic response to a crude cell extract of ovarian cancer cells has been studied in 48 patients with ovarian cancer (9, autologous, 39 allogeneic), in 26 female controls matched for age and in 18 female patients with other types of cancer in remission from disease. The responses in ovarian cancer patients in remission and relapse were considered separately. The blastogenic responses to cell extracts of foetal ovary, foetal lung, foetal liver and normal adult ovary were also assessed in a proportion of all 3 groups. The blastogenic responses to ovarian cancer and foetal ovary cell extracts were found to be significantly greater in the ovarian cancer patients in remission than in the controls, but the responses to ovarian cancer extract were not greater in the relapse group or in patients with other cancers. As a blastogenic response to normal ovarian extract was also present in some of these patients, the data so far do not support the hypothesis of a tumour specific antigen. This tumour associated response may be occurring to determinants in foetal or adult ovarian tissue to which the patient becomes sensitized in malignant disease. The response is complex and the nature of the antigen requires further analysis.
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm; D000939:Epitopes; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008099:Liver / Q000196:embryology / Q000276:immunology; D008168:Lung / Q000196:embryology / Q000276:immunology; D008213:Lymphocyte Activation; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology*; D010053:Ovary / Q000196:embryology / Q000276:immunology; D012075:Remission, Spontaneous
D000951:Antigens, Neoplasm; D000939:Epitopes